Holen Sie sich die Stockscreener-App
14.61
1.55%
-0.23
Handel nachbörslich:
14.61
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt NEO?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$14.84
Offen:
$14.65
24-Stunden-Volumen:
11.03M
Relative Volume:
3.97
Marktkapitalisierung:
$1.90B
Einnahmen:
$745.97M
Nettoeinkommen (Verlust:
$-99.21M
KGV:
-18.90
EPS:
-0.7729
Netto-Cashflow:
$-5.09M
1W Leistung:
+3.54%
1M Leistung:
+40.75%
6M Leistung:
+14.23%
1J Leistung:
+117.41%
1-Tages-Spanne:
$14.35
$15.04
1-Wochen-Bereich:
$13.80
$15.04
52-Wochen-Spanne:
$4.72
$15.57
Neogenomics Inc Stock (NEO) Company Profile
Firmenname
Neogenomics Inc
Sektor
Branche
Telefon
(239) 768-0600
Adresse
9490 NEOGENOMICS WAY, FORT MYERS, FL
Compare NEO vs TMO, DHR, IDXX, NTRA, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
14.61 | 1.93B | 745.97M | -99.21M | -5.09M | -0.7729 |
TMO
Thermo Fisher Scientific Inc
|
532.48 | 201.86B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
203.83 | 145.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
567.44 | 45.44B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
271.39 | 38.64B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
131.46 | 38.44B | 7.23B | 1.41B | 1.09B | 4.979 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-07-29 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-05-15 | Eingeleitet | Guggenheim | Neutral |
| 2025-04-30 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-01-13 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2024-12-10 | Eingeleitet | Jefferies | Buy |
| 2024-05-01 | Fortgesetzt | Craig Hallum | Buy |
| 2023-12-29 | Bestätigt | BTIG Research | Buy |
| 2023-08-21 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | Hochstufung | BTIG Research | Neutral → Buy |
| 2023-02-24 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-02-01 | Hochstufung | Needham | Hold → Buy |
| 2022-08-26 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-22 | Herabstufung | Needham | Buy → Hold |
| 2022-06-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-03-29 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-29 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | Fortgesetzt | Stephens | Overweight |
| 2021-12-16 | Eingeleitet | Cowen | Outperform |
| 2021-11-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-02-25 | Fortgesetzt | Needham | Buy |
| 2021-02-25 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-12-11 | Fortgesetzt | BTIG Research | Buy |
| 2020-10-28 | Bestätigt | Needham | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-08-28 | Eingeleitet | Guggenheim | Buy |
| 2020-07-29 | Bestätigt | Needham | Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Buy |
| 2020-04-21 | Fortgesetzt | Stephens | Overweight |
| 2020-03-02 | Fortgesetzt | Craig Hallum | Buy |
| 2020-02-28 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | Herabstufung | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | Bestätigt | Needham | Buy |
| 2019-05-01 | Bestätigt | Needham | Buy |
| 2019-03-29 | Bestätigt | Needham | Buy |
| 2019-01-03 | Eingeleitet | Needham | Buy |
| 2018-10-24 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | Eingeleitet | Leerink Partners | Outperform |
| 2018-05-02 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | Herabstufung | BTIG Research | Buy → Neutral |
| 2017-08-24 | Eingeleitet | Gabelli & Co | Buy |
| 2016-12-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Neogenomics Inc Aktie (NEO) Neueste Nachrichten
NGMS stock holds its ground after Neogenomics revenue trends improve - Ad Hoc News
PRPO vs. NEO: Which Cancer Diagnostics Stock Is the Better Buy? - The Globe and Mail
ETFs Investing in NeoGenomics, Inc. Stocks - TradingView
Bank of America Securities Reaffirms Their Hold Rating on NeoGenomics (NEO) - The Globe and Mail
Does NeoGenomics (NEO) New PTEN CDx Move Reveal a Deeper Precision Oncology Strategy Shift? - simplywall.st
NeoGenomics, Inc. Stock 12‑Month Price Target Raised to $15.67, Implies 11% Upside - TradingView
NeoGenomics Q1 2026 Earnings: Narrow Profit Beats Estimates Amid Market SkepticismRevenue Guidance Range - dars.gov.et
NeoGenomics Inc (NEO) Shares Fall 4.2% -- What GF Score of 72 Te - GuruFocus
NeoGenomics launches $275M convertible notes offering due 2032 - MSN
Press Release: NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026 - 富途牛牛
NeoGenomics (NEO) stock trades up, here is why - MSN
NeoGenomics (NEO) Stock Trades Up, Here Is Why - Yahoo Finance
NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer - BioSpace
NeoGenomics launches FDA-approved prostate cancer diagnostic test - Investing.com
NeoGenomics launches FDA-approved prostate cancer diagnostic test By Investing.com - Investing.com India
(NEO) Volatility Zones as Tactical Triggers - Stock Traders Daily
NeoGenomics Inc focuses on diagnostics growth as investors watch long-term margins - Ad-hoc-news.de
NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026 - BioSpace
NeoGenomics on Track for Longest Winning Streak Since February 2019 -- Data Talk - Moomoo
Neogenomics stock hits 52-week high at 15.56 USD By Investing.com - Investing.com South Africa
Neogenomics stock hits 52-week high at 15.56 USD - Investing.com
NEONeogenomics Inc Latest SEC Filings - Finviz
Is NeoGenomics (NEO) Quietly Reframing Its Oncology Data Strategy With Starrett’s Board Appointment? - simplywall.st
Price-Driven Insight from (NEO) for Rule-Based Strategy - Stock Traders Daily
NeoGenomics, Inc. Actuals & Estimates (NASDAQ:NEO) - TradingView
Enterprise value to EBITDA forward of NeoGenomics, Inc. – NASDAQ:NEO - TradingView
Price to sales forward of NeoGenomics, Inc. – NASDAQ:NEO - TradingView
Enterprise value to EBITDA forward of NeoGenomics, Inc. – MUN:NG9 - TradingView
NeoGenomics, Inc. Actuals & Estimates (BX:NG9) - TradingView
Price to book forward of NeoGenomics, Inc. – NASDAQ:NEO - TradingView
NeoGenomics, Inc. Actuals & Estimates (SWB:NG9) - TradingView
Price to earnings forward of NeoGenomics, Inc. – NASDAQ:NEO - TradingView
Enterprise value to EBIT forward of NeoGenomics, Inc. – NASDAQ:NEO - TradingView
Price to earnings forward of NeoGenomics, Inc. – LSX:120159 - TradingView
NeoGenomics, Inc. Hits New 52-Week High at $13.87 - MarketsMojo
Carolyn Starrett joins NeoGenomics board of directors team - Gulfshore Business
Enterprise value to revenue forward of NeoGenomics, Inc. – NASDAQ:NEO - TradingView
Enterprise value to EBITDA forward of NeoGenomics, Inc. – LSX:120159 - TradingView
A Look Back at Testing & Diagnostics Services Stocks’ Q1 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack - Yahoo Finance
NeoGenomics stock rallies to new highs with overbought signals raising volatility risk - Traders Union
NEO Forecast — Price Target — Prediction for 2027 - TradingView
Neogenomics stock hits 52-week high at 13.74 USD - Investing.com UK
Neogenomics stock hits 52-week high at 13.74 USD By Investing.com - Investing.com South Africa
NeoGenomics (NASDAQ: NEO) director receives new RSU and stock option grants - Stock Titan
NeoGenomics (NEO) director Carolyn Starrett files initial Form 3 - Stock Titan
NeoGenomics, Inc. Announces Appointment of Carolyn Starrett to Board of Directors - marketscreener.com
NeoGenomics Appoints Carolyn Starrett to its Board of Directors - 01net
NeoGenomics Taps AI Veteran for Board, Signaling Data-Driven Future - BriefGlance
NeoGenomics appoints Carolyn Starrett to board of directors By Investing.com - Investing.com Australia
NeoGenomics Appoints Carolyn Starrett to Board of Directors - citybiz
NeoGenomics Adds Data-Focused Independent Director to Board - TipRanks
Finanzdaten der Neogenomics Inc-Aktie (NEO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.61%
1.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):